Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors announced that the Company has been issued U.S. Patent #8,318,485 by the United States Patent and Trademark Office. This broad-based patent covers the treatment of diabetic retinopathy and other degenerative diseases of the eye with the Companys ischemic tolerant neural (itNSC) and mesenchymal (itMSC) stem cells. San Diego, CA (PRWEB) December 20, 2012 In the United States, diabetic retinopathy is the leading cause of new blindness in people 25-74 years of age. Approximately 700,000 persons in the United States have proliferative diabetic retinopathy. Each year another 65,000 are diagnosed with the condition. A recent study has estimated that, among people with diabetes aged 40 or older, 28.5% will develop diabetic retinopathy. Worldwide, it is estimated that 20 million people have proliferative diabetic retinopathy, with this number projected to increase to over 30 million by 2030. Diabetic retinopathy begins as a vascular condition with microaneurysms in the vessels of the retina. These blood vessels become blocked, thereby depriving portions of the retina from blood supply. This trauma causes the retina to secrete vascularization signals that result in new, fragile, abnormal blood vessels being formed. The … Continue reading →

Stemedica Cell Technologies, Inc., a leading manufacturer of adult ischemia tolerant allogeneic stem cells and stem cell factors announced that the Company has signed an agreement with The Scripps Research Institute to investigate the role of Stemedicas ischemia tolerant human mesenchymal stem cells and stem cell factors as a therapy for severe lung injury and sepsis. San Diego, CA (PRWEB) December 21, 2012 Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are the most common causes of respiratory failure among critically ill patients. The mortality for this syndrome remains high at 30-40% and accounts for approximately 75,000 deaths per year. Severe bacterial pneumonia is the most common cause of ALI/ARDS and is frequently associated with septic shock. The only intervention for ALI/ARDS that has resulted in a mortality benefit is low tidal volume ventilation. Despite several attempts, there have been no pharmacological agents that have reduced the morbidity or mortality from ALI/ARDS. Furthermore, treatment of bacterial pneumonia is increasingly hampered by the rapid spread of multi-drug resistant bacteria and the lack of new antimicrobial agents to treat them. Therefore, given the large public health impact of severe bacterial pneumonia and ALI/ARDS, novel therapies are needed to address this … Continue reading →